La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

nDatalyze Bilan de santé

Santé financière contrôle des critères 6/6

nDatalyze possède un total de capitaux propres de CA$889.6K et une dette totale de CA$0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont CA$947.0K et de CA$57.4K.

Informations clés

Ratio d'endettement

CA$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	CA$850.26k
Fonds propres	CA$889.59k
Total du passif	CA$57.36k
Total des actifs	CA$946.96k

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Is MedXtractor Corp.'s (CSE:MXT) 1.1% ROE Worse Than Average?

Jan 14

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de NDAT ( CA$867.5K ) dépassent ses passifs à court terme ( CA$57.4K ).

Passif à long terme: NDAT n'a pas de passif à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: NDAT est sans dette.

Réduire la dette: NDAT n'a eu aucune dette au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: NDAT dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: NDAT dispose d'une marge de trésorerie suffisante pour 1.9 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 32.8 % chaque année.

nDatalyze Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

nDatalyze Corp. Announces Positive Clinical Study Results, and Mindbalanced Update

New minor risk - Share price stability

nDatalyze Corp. Announces Change in President

Full year 2024 earnings released: CA$0.004 loss per share (vs CA$0.032 loss in FY 2023)

nDatalyze Corp. Announces Clinical Study Update

nDatalyze Corp. Updates the Clinical Study

nDatalyze Corp. announced that it has received CAD 0.20625 million in funding

nDatalyze Corp. announced that it expects to receive CAD 0.20625 million in funding

Ndatalyze Corp. Announces Executive Changes

nDatalyze Corp. (CNSX:NDAT) completed the acquisition of Mindbalanced Inc.

New minor risk - Share price stability

nDatalyze Corp., Annual General Meeting, Mar 14, 2024

Third quarter 2024 earnings released: CA$0.004 loss per share (vs CA$0.006 loss in 3Q 2023)

Insufficient new directors

New minor risk - Shareholder dilution

nDatalyze Corp. announced that it has received CAD 0.2778 million in funding

nDatalyze Corp. Announces Appointment of Dr. Keith Courtney as President and Chief Psychiatric Officer

Second quarter 2024 earnings released: EPS: CA$0.004 (vs CA$0.006 loss in 2Q 2023)

nDatalyze Corp. Advances Its Clinical Study Process

nDatalyze Corp. Begins a Clinical Study Process

nDatalyze Corp. Begins a Clinical Study Process

Full year 2023 earnings released: CA$0.032 loss per share (vs CA$0.032 loss in FY 2022)

Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.001 loss in 3Q 2022)

nDatalyze Corp. Anticipates YMI ChatGPT Testing

nDatalyze Corp. Announces Two Video Initiatives to Augment Its Phase 2 Marketing Program

nDatalyze Corp. Announces Canada-Wide Release of YMI

Second quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.003 loss in 2Q 2022)

nDatalyze Corp., Annual General Meeting, Nov 30, 2022

First quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.002 loss in 1Q 2022)

Full year 2022 earnings released: CA$0.032 loss per share (vs CA$0.027 loss in FY 2021)

nDatalyze Announces YMI mHealth Application Beta is Now Online

nDatalyze Corp. announced that it expects to receive CAD 1.25 million in funding

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

nDatalyze Announces Successful Proof-Of-Concept and Progress Update

Second quarter 2022 earnings released: CA$0.003 loss per share (vs CA$0.001 profit in 2Q 2021)

First quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.001 profit in 1Q 2021)

Medxtractor Corp Updates Reference Record Collection Progress

Full year 2021 earnings released: CA$0.027 loss per share (vs CA$0.002 loss in FY 2020)

MedXtractor Corp. announced that it has received CAD 1.815 million in funding

President exercised options and sold CA$78k worth of stock

Chief Financial Officer recently sold CA$99k worth of stock

New 90-day high: CA$0.27

MedXtractor Corp. announced that it expects to receive CAD 1.6 million in funding

Medxtractor Corp. Updates the SHAMAN Psychedelics Artificial Intelligence Project

New 90-day high: CA$0.24

New 90-day high: CA$0.21

Is MedXtractor Corp.'s (CSE:MXT) 1.1% ROE Worse Than Average?

Medxtractor Corp. Announces Commencement of "SHAMAN"

Third quarter 2021 earnings released: CA$0.001 loss per share

MedXtractor Corp. Announces Board Changes

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines